Cancer Therapy

Ralph A. Reisfeld

ISBN 10: 3642737234 / ISBN 13: 9783642737237

Published by Springer Berlin Heidelberg Nov 2011, 2011

About this Item

This item is printed on demand - it takes 3-4 days longer - Neuware -A variety of new cancer therapy modalities are discussed and evaluated in this book. It aims to demonstrate that the combination of classical chemo- and radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and monoclonal antibodies against gastrointestinal tumors and melanoma are included. The progress in regional chemotherapy strategies, for example of the liver, is shown. In addition, the development of new chemotherapeutic agents with a different mode of action as well as better tolerability is presented. The use of hormones, such as LH-RH agonists, allows hormone-dependent tumors such as prostatic and breast cancer to be treated without strong adverse reactions. These recent findings give the reader insight into exciting therapeutic directions made possible by such combined, rather than single, modalities. 324 pp. Englisch.

Seller Inventory # 9783642737237

Bibliographic Details

• Title: Cancer Therapy
• Publisher: Springer Berlin Heidelberg Nov 2011
• Publication Date: 2011
• Language: English
• ISBN 10: 3642737234
• ISBN 13: 9783642737237
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 244W x 170H x 18D millimeters 244 millimeters width by 170 millimeters height by 18 millimeters depth
• Weight: 562 grams

About this title

Synopsis

A variety of new cancer therapy modalities are discussed and evaluated in this book. It aims to demonstrate that the combination of classical chemo- and radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and monoclonal antibodies against gastrointestinal tumors and melanoma are included. The progress in regional chemotherapy strategies, for example of the liver, is shown. In addition, the development of new chemotherapeutic agents with a different mode of action as well as better tolerability is presented. The use of hormones, such as LH-RH agonists, allows hormone-dependent tumors such as prostatic and breast cancer to be treated without strong adverse reactions. These recent findings give the reader insight into exciting therapeutic directions made possible by such combined, rather than single, modalities.